Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

被引：1
|
作者：
Piccini, Matteo [1 ]
Pilerci, Sofia [2 ]
Scappini, Barbara [2 ]
Mannelli, Francesco [3 ]
Ciolli, Gaia [4 ]
Pasquini, Andrea [4 ]
Fasano, Laura [4 ]
Quinti, Elisa [4 ]
Guglielmelli, Paola [5 ]
Mannarelli, Carmela [5 ]
Pancani, Fabiana [5 ]
Zizza, Michela [5 ]
Signori, Leonardo [5 ]
Vannucchi, Alessandro M. [6 ]
Gianfaldoni, Giacomo [2 ]
机构：
[1] Univ Firenze, AOU Careggi, SOD Ematol, Florence, Italy
[2] Azienda Osped Univ Careggi, SOD Ematol, Florence, Italy
[3] Azienda Osped Univ Careggi, CRIMM Ctr Res & Innovat Myeloproliferat Neoplasms, SOD Ematol, Florence, Italy
[4] Univ Firenze, Azienda Osped Univ Careggi, Scuola Specializzaz Ematol, SOD Ematol, Florence, Italy
[5] Univ Florence, Ctr Res & Innovat Myeloproliferat Neoplasms, AOU Careggi, CRIMM, Florence, Italy
[6] Univ Firenze, CRIMM Ctr Ric & Innovaz Malattie Mieloproliferat, Azienda Osped Univ Careggi, Florence, Italy
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163212
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
615
引用
收藏
页码：9008 / 9009
页数：2
相关论文
共 50 条
  • [21] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
  • [22] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Zucenka, Andrius
    Maneikis, Kazimieras
    Pugaciute, Birute
    Ringeleviciute, Ugne
    Dapkeviciute, Austeja
    Davainis, Linas
    Daukelaite, Guoda
    Burzdikaite, Paulina
    Staras, Vytautas
    Griskevicius, Laimonas
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1195 - 1202
  • [23] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Andrius Zucenka
    Kazimieras Maneikis
    Birute Pugaciute
    Ugne Ringeleviciute
    Austeja Dapkeviciute
    Linas Davainis
    Guoda Daukelaite
    Paulina Burzdikaite
    Vytautas Staras
    Laimonas Griskevicius
    Annals of Hematology, 2021, 100 : 1195 - 1202
  • [24] Azacytidine and Venetoclax as a Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia: A Single Centre Experience
    Mondal, Saikat
    Gupta, Deepika
    Vairamoorthy, Naveen
    Moule, Priyanka
    Kotwal, Jyoti
    Gupta, Nitin
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025, 41 (01) : 197 - 199
  • [25] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [26] Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
    Baez-Gutierrez, Nerea
    Rodriguez-Ramallo, Hector
    Antonia-Perez Moreno, Maria
    Arboli, Eduardo-Rodriguez
    Abdel-Kader Martin, Laila
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [27] Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
    Pollyea, Daniel A.
    Jordan, Craig T.
    CURRENT OPINION IN HEMATOLOGY, 2019, 26 (02) : 71 - 76
  • [28] Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting
    Zucenka, Andrius
    Vaitekenaite, Vilmante
    Maneikis, Kazimieras
    Pileckyte, Regina
    Trociukas, Igoris
    Peceliunas, Valdas
    Griskevicius, Laimonas
    BLOOD, 2021, 138
  • [29] Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.
    Karol, Seth E.
    Alexander, Thomas
    Das Gupta, Soumyasri
    Pounds, Stanley B.
    Canavera, Kristin
    Klco, Jeffery M.
    Lacayo, Norman James
    Pui, Ching-Hon
    Opferman, Joseph T.
    Rubnitz, Jeffrey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Safety and Efficacy of Venetoclax Combined with Hypomethylating Agents or Low-Dose Cytarabine for Acute Myeloid Leukemia before and after Allogeneic Hematopoietic Cell Transplantation
    Pessoa Mendes, Rafael Fernandes
    Fatobene, Giancarlo
    Molla, Vinicius
    Helman, Ricardo
    Rodrigues, Morgani
    Schmidt Filho, Jayr
    Novis, Yana
    Rodrigues, Celso Arrais
    Rocha, Vanderson
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S300 - S300
12345